Company overview
Cellectricon provides customized in vitro neurobiology services for pharmaceutical drug discovery, focusing on areas like neurotoxicity, neuroinflammation, neurodegeneration, and neuroplasticity. They utilize proprietary technologies such as Cellaxess® for cell engineering and selective stimulation, and Dynaflow® for ion channel research, alongside advanced assays integrating optical electrophysiology and high-content imaging. These services support early target identification, lead optimization, and safety assessment using physiologically relevant cell and tissue models.
Cellectricon is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cellectricon, in vitro neurobiology, neurotoxicity testing, cellaxess technology, drug discovery services.
Structured facts
- Website
- https://cellectricon.com
- Markets served
- United States & Americas
- Keywords
- cellectricon, in vitro neurobiology, neurotoxicity testing, cellaxess technology, drug discovery services
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What core services does Cellectricon offer for pharma R&D?
- Cellectricon offers customized in vitro neurobiology services including neurotoxicity testing, neuroinflammation models, neurodegeneration assays, and neuroplasticity screening to accelerate early drug discovery programs.
- What proprietary technologies does Cellectricon use?
- Key technologies include Cellaxess® for high-resolution ion-channel screening, cell engineering, and selective field stimulation of excitable cells, plus Dynaflow® for ion channel research and discovery applications.
- What therapeutic areas and models does Cellectricon specialize in?
- Specialties cover peripheral neuropathies, neuroinflammation, neurodegeneration, and neuroplasticity, using advanced in vitro models with primary cells, stem cells, optical electrophysiology, high-content imaging, and microfluidic systems.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
